Clinical Trails

The phase 2 CHIMERA trial is evaluating whether adding pembrolizumab to standard chemotherapy before and after surgery can improve outcomes for patients with resectable pleural mesothelioma. About 40 adults with previously untreated stage I to IIIa epithelioid or biphasic disease are expected to enroll. Patients will receive three cycles of pembrolizumab combined with platinum-based chemotherapy […]

Updated results from the phase 2 J201 study show that safusidenib continues to demonstrate promising long-term activity in patients with treatment-naive grade 2 IDH1-mutant glioma. After a median follow-up of 38.8 months, the drug achieved a confirmed overall response rate of 51.9%, while 79.1% of patients remained free from disease progression at 36 months. The

Results from the phase 2 KEYPAD trial suggest that combining pembrolizumab with denosumab may benefit patients with advanced clear-cell renal cell carcinoma (ccRCC) whose cancer progressed after previous VEGFR-targeted therapy. The Australian single-arm study enrolled 59 patients with unresectable or metastatic disease. The combination achieved an objective response rate of 31%, with all responses being

Preliminary results from an ongoing phase 2 trial suggest that adding the investigational drug BPM31510 to standard chemoradiation may improve survival for patients with newly diagnosed glioblastoma. Among 39 evaluable patients, the median overall survival was 19.3 months, exceeding the survival typically seen with standard treatment alone. The greatest benefit was seen in patients with

A phase 2 trial found that neoadjuvant cemiplimab (Libtayo) produced encouraging results in 35 patients with locally advanced head and neck basal cell carcinoma who had not received Hedgehog inhibitor therapy. The treatment achieved a 60.1% objective response rate and a 91.4% disease control rate. Responding patients had an average tumor reduction of 70%, with

A phase 2 trial found that adjuvant penpulimab-kcqx (Anikora) significantly improved disease-free survival in patients with very high-risk clear cell renal cell carcinoma after surgery. The study enrolled 174 patients after nephrectomy. Half received IV penpulimab every three weeks for up to 17 cycles, while the other half underwent standard observation. Penpulimab reduced the risk

Interim results from the phase 2 THIO-101 trial show that the investigational drug ateganosine (THIO), followed by the PD-1 inhibitor cemiplimab (Libtayo), achieved a 90.5% disease control rate in heavily pretreated patients with advanced non-small cell lung cancer (NSCLC). Among 21 patients evaluated, 19 experienced either a complete response, partial response, or stable disease. This

Updated results from a Phase 2a clinical trial suggest that namodenoson (CF102), an oral A3 adenosine receptor agonist, may provide lasting disease control for patients with advanced pancreatic ductal adenocarcinoma (PDAC) who have already received multiple rounds of treatment. The study met its main safety goal, with no new safety concerns reported in patients receiving

ST-001 SST-001 nanoFenretinide showed promising early results in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL), including mycosis fungoides and Sézary syndrome, who had limited treatment options. In the Phase 1a trial, 25 heavily pretreated patients received the drug as a daily intravenous infusion for five days every three weeks. The overall response rate

A phase 2 study found that retreating older patients with relapsed multiple myeloma using daratumumab, lenalidomide, and dexamethasone (DRd) remained effective even after previous daratumumab-based treatment. The GMMG-DADA trial enrolled 67 transplant-ineligible patients with a median age of 74, including many with severe kidney disease who are often excluded from clinical trials. During first-line treatment,